On 02 February 2023, in a Phase II, Open-Label, Randomized, Active-Controlled Pilot Study, the first patient was successfully treated with Skingenix’s investigational drug, MW-III by the investigator Jeffrey Shupp, MD, at MedStar Washington Hospital Center, in USA. This clinical study is currently ongoing, in which a total of 60 patients with Second-Degree Thermal Burns, will be enrolled and randomized to either investigational drug MW-III (30 patients) or active control (30 patients) Silvadene® Cream 1% (Silver Sulfadiazine). The study is currently recruiting eligible patients with Second-Degree Thermal Burns and is expected to be completed in 2023. For further details, please visit clinicaltrials.gov website (NCT01297400).

Skingenix, Inc. announces successful completion of a Phase II, Randomized, Controlled, Multi-Center Study to assess the Safety and Efficacy of their investigational product in patients with Diabetic Foot Ulcers. This clinical study was completed in December 2013 , more information can be found at www.clinicaltrials.gov

On 9 October 2012, in a Phase II randomized and controlled multicenter clinical trial, the first subject was successfully treated with Skingenix’s investigational product in USA. This clinical study is currently ongoing, in which a total of 35 patients with Diabetic Foot Ulcers will be treated with the investigational product. The study is currently recruiting eligible patients with Diabetic Foot Ulcers and is expected to be completed in 2013. For further details, please visit clinicaltrials.gov website.

Under an Investigational New Drug Application (IND), Skingenix has successfully  completed two pilot clinical studies in USA :

1. First clinical study was conducted in patients with Venous Leg Ulcer.
2. The second clinical study was conducted in patients with Diabetic Foot Ulcers.

These studies were completed in December 2011.